PMID- 30854085
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 10
IP  - 4
DP  - 2019
TI  - VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A 
      systematic review.
PG  - 799-809
LID - 10.7150/jca.29643 [doi]
AB  - Introduction: To estimate the efficacy and safety of vascular endothelial growth 
      factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in combination with 
      chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). 
      Methods: We searched PubMed, PMC database, EMBASE, EBSCO-Medline, Cochrane 
      Central Register of Controlled Trials (CENTRAL), American Society of Clinical 
      Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC) 
      and the European Society of Medical Oncology (ESMO), 
      http://www.clinicaltrials.gov/, CNKI, and Wanfang databases to identify primary 
      research reporting the survival outcomes and safety of VEGFR-TKIs in patients 
      with advanced NSCLC. A meta-analysis was conducted to generate combined hazard 
      ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR), disease control 
      rate (DCR), and risk ratios (RRs) with 95% CI for adverse events (AEs). Results: 
      A total of 20 RCTs (8,366 participants) were included. The VEGFR-TKIs resulted in 
      improved PFS (HR 0.82, 95% CI 0.78-0.87), ORR (HR 1.72, 95% CI 1.34-2.22), and 
      DCR (1.45, 1.26-1.67) in patients with advanced NSCLC, but had no impact on OS 
      (HR 0.94, 95% CI 0.89-1.00). The incidence of some high grade (>/= 3) AEs 
      increased, such as hemorrhage, hypertension and neutropenia. Conclusions: Our 
      study demonstrated that regimens with VEGFR-TKIs combined with chemotherapy 
      improved PFS, ORR and DCR in patients with advanced NSCLC, but had no impact on 
      OS. VEGFR-TKIs induced more frequent and serious AEs compared with control 
      therapies.
FAU - Liu, Lian
AU  - Liu L
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Wei, Jia
AU  - Wei J
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Chen, Zhaoxin
AU  - Chen Z
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
FAU - Yu, Jing
AU  - Yu J
AD  - Cancer Center, Beijing Friendship Hospital, Capital Medical University, No. 95 
      Yong An Road, Xi Cheng District, Beijing, 100050, China.
LA  - eng
PT  - Journal Article
DEP - 20190130
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC6400799
OTO - NOTNLM
OT  - VEGFR-TKIs
OT  - chemotherapy
OT  - efficacy
OT  - meta-analysis
OT  - non-small cell lung cancer
OT  - safety
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2019/03/12 06:00
MHDA- 2019/03/12 06:01
PMCR- 2019/01/01
CRDT- 2019/03/12 06:00
PHST- 2018/09/01 00:00 [received]
PHST- 2019/01/09 00:00 [accepted]
PHST- 2019/03/12 06:00 [entrez]
PHST- 2019/03/12 06:00 [pubmed]
PHST- 2019/03/12 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - jcav10p0799 [pii]
AID - 10.7150/jca.29643 [doi]
PST - epublish
SO  - J Cancer. 2019 Jan 30;10(4):799-809. doi: 10.7150/jca.29643. eCollection 2019.